Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season

• Main Author: Rondy, Marc
• Publication Date: 2017
• Other Authors: Gherasim, Alin, Casado, Itziar, Launay, Odile, Rizzo, Caterina, Pitigoi, Daniela, Mickiene, Aukse, Marbus, Sierk D, Machado, Ausenda, Syrjänen, Ritva K, Pem-Novose, Iva, Horváth, Judith Krisztina, Larrauri, Amparo, Castilla, Jesús, Vanhems, Philippe, Alfonsi, Valeria, Ivanciuc, Alina E, Kuliese, Monika, van Gageldonk-Lafeber, Rianne, Gomez, Veronica, Ikonen, Niina, Lovric, Zvjezdana, Ferenczi, Annamária, Moren, Alain, I-MOVE+ hospital working group
• Format: Article
• Language: eng
• Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
• Download full: http://hdl.handle.net/10400.18/5071
• topic: A(H3N2); Influenza; Cases Control;; Elderly; Hospitalisation; Vaccine Effectiveness; Vacina Antigripal; Cuidados de Saúde; Efetividade da Vacina Antigripal

In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65-79-year-olds and 13% (95% CI: -15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate.